SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational miroliverELAP®, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood cir.

Guru Stock PicksBrandes Investment Partners, LP has made the following transactions:Add in KMT by 0.94%Stock News Stocks steady into Iran deadline: The S&P 500

BAM Wealth Management LLC purchased a new position in United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 886 shares of the biotechnology company's stock, valued at approximately $432,000. Other hedge funds have

Element Squared LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ: UTHR) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,027 shares of the biotechnology company's stock, valued at approximately $2,449,000. United Therapeutics accounts for 1.3%

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total value of $4,696,721.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $593.17, for a total transaction of $5,931,700.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company's

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $581.63, for a total value of $5,525,485.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $590.59, for a total transaction of $5,610,605.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the